These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 9272114

  • 21. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 22. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 23. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 11; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 24. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 25. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR.
    Cancer Chemother Pharmacol; 1992 Dec 15; 30(1):43-50. PubMed ID: 1586979
    [Abstract] [Full Text] [Related]

  • 26. Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer.
    Liang Z, Bian D.
    Chin Med J (Engl); 1996 May 15; 109(5):353-5. PubMed ID: 9208490
    [Abstract] [Full Text] [Related]

  • 27. [Modulation of cisplatin cytotoxicity by amphotericin B in six human cell lines of medullary thyroid cancer].
    Massart C, Gibassier J, Le Gall F, Raoul ML, Leclech G, Lucas C.
    Bull Cancer; 1996 Aug 15; 83(8):619-25. PubMed ID: 8869041
    [Abstract] [Full Text] [Related]

  • 28. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y, Imai S, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Tobe T.
    Anticancer Res; 1991 Aug 15; 11(2):761-7. PubMed ID: 2064331
    [Abstract] [Full Text] [Related]

  • 29. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2004 Aug 15; 94(2):404-8. PubMed ID: 15297180
    [Abstract] [Full Text] [Related]

  • 30. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF, Hunakova L, Kelland LR.
    Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899
    [Abstract] [Full Text] [Related]

  • 31. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X, Lou LG, Sui DH, Wu XH.
    Asian Pac J Cancer Prev; 2014 Nov 15; 15(22):9939-43. PubMed ID: 25520132
    [Abstract] [Full Text] [Related]

  • 32. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
    Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH.
    Cancer Chemother Pharmacol; 1998 Nov 15; 41(3):186-92. PubMed ID: 9443634
    [Abstract] [Full Text] [Related]

  • 33. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T.
    Int J Gynecol Cancer; 2012 Jul 15; 22(6):922-9. PubMed ID: 22672985
    [Abstract] [Full Text] [Related]

  • 34. [Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer].
    Liang Z, Bian D.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb 15; 31(2):75-8. PubMed ID: 8758797
    [Abstract] [Full Text] [Related]

  • 35. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB.
    Clin Cancer Res; 2004 Jul 15; 10(14):4661-9. PubMed ID: 15269138
    [Abstract] [Full Text] [Related]

  • 36. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L, Luan Y, Wang G, Tang B, Li D, Zhang W, Li X, Zhao J, Ding H, Reed E, Li QQ.
    Int J Mol Med; 2004 Aug 15; 14(2):257-64. PubMed ID: 15254775
    [Abstract] [Full Text] [Related]

  • 37. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 38. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP, Perez KM, Handel LM, Hamilton TC.
    Cancer Chemother Pharmacol; 1992 Nov 15; 29(6):430-4. PubMed ID: 1568285
    [Abstract] [Full Text] [Related]

  • 39. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
    Sawers L, Ferguson MJ, Ihrig BR, Young HC, Chakravarty P, Wolf CR, Smith G.
    Br J Cancer; 2014 Sep 09; 111(6):1150-8. PubMed ID: 25010864
    [Abstract] [Full Text] [Related]

  • 40. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 09; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.